Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND WORLD: Lisocabtagene maraleucel in aggressive B-cell non-Hodgkin lymphoma
2017-000106-38Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Primary endpoint: Overall Response Rate in non-Hodgkin lymphoma (including secondary CNS involvement). Started Mar 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2017-000106-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000106-38.